-
Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation block Blood Cancer J. (IF 12.9) Pub Date : 2025-02-13 Jiexian Ma, Shunrong Sun, Yanhui Xie, Songlin Zhou, Min Wu, Xinyu Zuo, Mixue Xie, Xiaoqin Wang
-
Comparing the efficacy and safety of venetoclax combined with hypomethylating agents versus intensive chemotherapy as induction therapy in newly diagnosed core binding factor acute myeloid leukemia patients Blood Cancer J. (IF 12.9) Pub Date : 2025-02-11 Jingyi Shen, Meng Shan, Mengqian Chu, Yiming Cai, Jingwen Rui, Suning Chen, Depei Wu, Yang Xu
-
Defining 'Intention' in intention-to-treat survival outcomes for chimeric antigen receptor T-cell therapy. Blood Cancer J. (IF 12.9) Pub Date : 2025-02-08 Charles J Milrod,Rebecca Steuer,Ari Pelcovits
-
The clinical journey of belantamab mafodotin in relapsed or refractory multiple myeloma: lessons in drug development Blood Cancer J. (IF 12.9) Pub Date : 2025-02-07 Pralay Mukhopadhyay, Hesham A. Abdullah, Joanna B. Opalinska, Prani Paka, Eric Richards, Katja Weisel, Suzanne Trudel, Maria-Victoria Mateos, Meletios Athanasios Dimopoulos, Sagar Lonial
-
Genomic characterization of chronic lymphocytic leukemia in patients of African ancestry Blood Cancer J. (IF 12.9) Pub Date : 2025-02-06 Cecilia Bonolo de Campos, Chantal E. McCabe, Laura A. Bruins, Daniel R. O’Brien, Sochilt Brown, Renee C. Tschumper, Cristine Allmer, Yuan Xiao Zhu, Kari G. Rabe, Sameer A. Parikh, Neil E. Kay, Huihuang Yan, James R. Cerhan, John N. Allan, Richard R. Furman, J. Brice Weinberg, Danielle M. Brander, Diane F. Jelinek, Marta Chesi, Susan L. Slager, Esteban Braggio
-
Implications of isolated MRD progression in newly diagnosed multiple myeloma treated with quadruplet therapy Blood Cancer J. (IF 12.9) Pub Date : 2025-02-05 Luciano J. Costa, Eva Medvedova, Binod Dhakal, Bhagirathbhai R. Dholaria, Kelly N. Godby, Susan Bal, Gayathri Ravi, Smith Giri, Saurabh Chhabra, Rebecca Silbermann, Natalie S. Callander
-
Efficacy and safety of CAR-T cell therapy in B-ALL patients previously treated with blinatumomab Blood Cancer J. (IF 12.9) Pub Date : 2025-02-05 Yurou Chu, Biqi Zhou, Rui Gao, Miao Miao, Huiying Qiu, Xiaowen Tang, Ying Wang, Suning Chen, Liqing Kang, Depei Wu, Yang Xu
-
Luspatercept for the treatment of anemia in allo-HSCT for patients with hematological diseases Blood Cancer J. (IF 12.9) Pub Date : 2025-02-05 Xiangke Xin, Wenli Zhang, Zhen Li, Ruirui Gui, Juan Wang, Liyun Ji, Yanli Zhang, Baijun Fang, Yongping Song, Yingling Zu, Jian Zhou
-
Exploring BCL2 regulation and upstream signaling transduction in venetoclax resistance in multiple myeloma: potential avenues for therapeutic intervention Blood Cancer J. (IF 12.9) Pub Date : 2025-02-05 Rodrigo Fonseca, Yuan Xiao Zhu, Laura A. Bruins, Joseph Ahmann, Cecilia de Bonolo Campos, Esteban Braggio, Xianfeng Chen, Mariano Arribas, Susie Darvish, Seth Welsh, Erin Meermeier, Kiran K. Mangalaparthi, Richard K. Kandasamy, Greg Ahmann, J. Erin Wiedmeier-Nutor, Akhilesh Pandey, Marta Chesi, P. Leif Bergsagel, Rafael Fonseca
-
Bruton’s tyrosine kinase inhibition re-sensitizes multidrug-resistant DLBCL tumors driven by BCL10 gain-of-function mutants to venetoclax Blood Cancer J. (IF 12.9) Pub Date : 2025-02-02 Caroline A. Coughlin, Dhanvantri Chahar, Marianna Lekakis, Abdessamad A. Youssfi, Lingxiao Li, Evan Roberts, Natalia Campos Gallego, Claude-Henry Volmar, Ola Landgren, Shaun Brothers, Anthony J. Griswold, Catalina Amador, Daniel Bilbao, Francesco Maura, Jonathan H. Schatz
-
CALRins5-mediated clonal hematopoiesis causes severe hemolytic anemia in a female PGK1Ser320Asn carrier Blood Cancer J. (IF 12.9) Pub Date : 2025-02-01 M. L. Morales, H. Cano, B. de la Morena-Barrio, J. L. Vives-Corrons, E. J. Cuenca-Zamora, P. Garrido-Rodríguez, C. Bento, J. Pereira, J. Martínez Nieto, T. H. Chen-Liang, J. L. Fuster, S. Caracena, M. L. Lozano, R. Teruel-Montoya, J. Corral, F. Ferrer-Marín
-
GATA2 mutated allele specific expression is associated with a hyporesponsive state of HSC in GATA2 deficiency syndrome Blood Cancer J. (IF 12.9) Pub Date : 2025-01-30 Laetitia Largeaud, Vincent Fregona, Laura A. Jamrog, Camille Hamelle, Stéphanie Dufrechou, Naïs Prade, Esmaa Sellam, Pauline Enfedaque, Manon Bayet, Sylvie Hébrard, Mathieu Bouttier, Christine Didier, Bastien Gerby, Eric Delabesse, Marlène Pasquet, Cyril Broccardo
-
Fedratinib for the treatment of myelofibrosis: a critical appraisal of clinical trial and “real-world” data Blood Cancer J. (IF 12.9) Pub Date : 2025-01-14 Adrian Duek, Ilona Leviatan, Osnat Jarchowsky Dolberg, Martin H. Ellis
Fedratinib is a predominantly JAK2 inhibitor that has shown efficacy in untreated and ruxolitinib-exposed patients with myelofibrosis (MF). Based on randomized clinical trial data, it is approved for use in patients with International Prognostic Scoring System (IPSS) or Dynamic International Prognostic Scoring System (DIPSS) intermediate-2 or high-risk disease and is distinguished from ruxolitinib
-
Whole genome sequencing and the genetics of extramedullary disease in multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2025-01-12 Nicholas Bingham, Jaynish Shah, Daniel Wong, Sueh-li Lim, Krystal Bergin, Anna Kalff, Antonia Reale, Tiffany Khong, Sridurga Mithraprabhu, Andrew Spencer
-
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group Blood Cancer J. (IF 12.9) Pub Date : 2025-01-11 Guadalupe Oñate, Ana Garrido, Montserrat Arnan, Helena Pomares, Ester Alonso, Mar Tormo, Marina Diaz-Beya, Susana Vives, Lurdes Zamora, Antonia Sampol, Rosa Coll, Olga Salamero, Marta Cervera, Antoni Garcia, Ferran Vall-Llovera, Sara Garcia-Avila, Joan Bargay, Xavier Ortin, Eva Iranzo, Francisca Guijarro, Marta Pratcorona, Josep F. Nomdedeu, Jordi Esteve, Jorge Sierra
-
Tunneling nanotubes between bone marrow stromal cells support transmitophagy and resistance to apoptosis in myeloma Blood Cancer J. (IF 12.9) Pub Date : 2025-01-09 Antonio Giovanni Solimando, Francesco Di Palma, Vanessa Desantis, Angelo Vacca, Maria Svelto, Francesco Pisani
-
Treatment with obinutuzumab plus venetoclax reshapes the TRB repertoire of CLL patients Blood Cancer J. (IF 12.9) Pub Date : 2025-01-07 Paul J. Hengeveld, Joyce Schilperoord-Vermeulen, P. Martijn Kolijn, Julie M. N. Dubois, Peter E. Westerweel, Sabina Kersting, Arnon P. Kater, Mark-David Levin, Anton W. Langerak
-
Updated analysis of EMN02 demonstrated overall survival benefit to early ASCT for multiple myeloma. Blood Cancer J. (IF 12.9) Pub Date : 2025-01-03 Alfred L Garfall
-
Integration of clinical outcomes and molecular features in extramedullary disease in multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2024-12-23 Rie Nakamoto-Matsubara, Valentina Nardi, Nora Horick, Tsuyoshi Fukushima, Ryan S. Han, Rajib Shome, Kiyosumi Ochi, Cristina Panaroni, Keertik Fulzele, Farah Rexha, Andrew R. Branagan, Diana Cirstea, Andrew J. Yee, David T. Scadden, Noopur S. Raje
-
Global disparities in drug-related adverse events of patients with multiple myeloma: a pharmacovigilance study Blood Cancer J. (IF 12.9) Pub Date : 2024-12-20 Majid Jaberi-Douraki, Xuan Xu, Danai Dima, Sikander Ailawadhi, Faiz Anwer, Sandra Mazzoni, Jason Valent, Muhammad Hamza Habib, Jim E. Riviere, Shahzad Raza
-
Clinical characteristics and outcomes of 476 mantle cell lymphoma patients aged 80 years and older Blood Cancer J. (IF 12.9) Pub Date : 2024-12-19 Simon Pahnke, Kossi D. Abalo, Sara Ekberg, Alexandra Albertsson-Lindblad, Karin E. Smedby, Mats Jerkeman, Ingrid Glimelius
-
The significance of free light-chain ratio in light-chain monoclonal gammopathy of undetermined significance: a flow cytometry sub-study of the iStopMM screening study Blood Cancer J. (IF 12.9) Pub Date : 2024-12-18 Jón Þórir Óskarsson, Sæmundur Rögnvaldsson, Sigrun Thorsteinsdottir, Thorir Einarsson Long, Andri Ólafsson, Elias Eythorsson, Ásbjörn Jónsson, Brynjar Viðarsson, Páll T. Önundarson, Bjarni A. Agnarsson, Róbert Pálmason, Margrét Sigurðardóttir, Ingunn Þorsteinsdóttir, Ísleifur Ólafsson, Stephen J. Harding, Brian G. M. Durie, Thorvardur Jon Love, Sigurdur Y. Kristinsson
-
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM Blood Cancer J. (IF 12.9) Pub Date : 2024-12-18 Florent Malard, Arthur Bobin, Myriam Labopin, Lionel Karlin, Laurent Frenzel, Murielle Roussel, Marguerite Vignon, Sophie Godet, Thomas Chalopin, Perrine Moyer, Emilie Chalayer, Frederique Orsini Piocelle, Clara Mariette, Carolyne Croizier, Claudine Sohn, Mamoun Dib, Ronan Le Calloch, Nadia Ali-Ammar, Marion Loirat, Omar Benbrahim, Alexandre Payssot, Adrien Trebouet, Aurore Perrot, Xavier Leleu, Mohamad
-
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study Blood Cancer J. (IF 12.9) Pub Date : 2024-12-18 Yi Zhang, Hu Zhou, Shanshan Suo, Junling Zhuang, Linhua Yang, Aili He, Qingchi Liu, Xin Du, Sujun Gao, Yarong Li, Yan Li, Yuqing Chen, Wen Wu, Huanling Zhu, Guangsheng He, Mei Hong, Qian Jiang, Zhongxing Jiang, Hongmei Jing, Jishi Wang, Na Xu, Lingling Yue, Cuiping Zheng, Zeping Zhou, Chenghao Jin, Xin Li, Lin Liu, Yajing Xu, Dengshu Wu, Feng Zhang, Jin Zhang, Liqing Wu, Hewen Yin, Binhua Lv, Zhijian
-
Transcriptomic clustering of chronic lymphocytic leukemia: molecular subtypes based on Bruton’s tyrosine kinase expression levels Blood Cancer J. (IF 12.9) Pub Date : 2024-12-18 Gorkem Kismali, Ganiraju Manyam, Nitin Jain, Cristina Ivan, Betty Lamothe, Mary L. Ayres, LaKesla R. Iles, William G. Wierda, Varsha Gandhi
-
Single-cell transcriptomic and spatial analysis reveal the immunosuppressive microenvironment in relapsed/refractory angioimmunoblastic T-cell lymphoma Blood Cancer J. (IF 12.9) Pub Date : 2024-12-18 Mengyan Zhu, Ning Li, Lei Fan, Rongrong Wu, Lei Cao, Yimin Ren, Chuanyang Lu, Lishen Zhang, Yun Cai, Yuzhu Shi, Zihan Lin, Xueying Lu, Jiayan Leng, Shiyang Zhong, Xingfei Hu, Bin Huang, Runheng Huang, Wanting Zhou, Diru Yao, Lingxiang Wu, Wei Wu, Quanzhong Liu, Peng Xia, Ruize Chen, Wenyu Shi, Ruohan Zhang, Sali Lv, Chunling Wang, Liang Yu, Jianyong Li, Qianghu Wang, Kening Li, Hui Jin
-
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity Blood Cancer J. (IF 12.9) Pub Date : 2024-12-18 Vaishali Bhardwaj, Zhi-Zhang Yang, Shahrzad Jalali, Jose C. Villasboas, Rekha Mudappathi, Junwen Wang, Prithviraj Mukherjee, Jonas Paludo, Xinyi Tang, Hyo Jin Kim, Jordan E. Krull, Kerstin Wenzl, Anne J. Novak, Patrizia Mondello, Stephen M. Ansell
-
Real-world characteristics and outcomes of patients with high-risk and non-high-risk smoldering multiple myeloma using the Flatiron Health database Blood Cancer J. (IF 12.9) Pub Date : 2024-12-05 S. Vincent Rajkumar, María-Victoria Mateos, Marcy Schaeffer, Xiwu Lin, Sacheeta Bathija, Niodita Gupta-Werner, Annette Lam, Robin Carson, Robyn Dennis, Shuchita Kaila, Kathryn Matt, Joana Duran, Sagar Lonial
-
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy Blood Cancer J. (IF 12.9) Pub Date : 2024-12-05 Maximilian Merz, Danai Dima, Hamza Hashmi, Nausheen Ahmed, Friedrich Stölzel, Tobias A. W. Holderried, Roland Fenk, Fabian Müller, Natalia Tovar, Aina Oliver-Cáldes, Kristin Rathje, James A. Davis, David Fandrei, Vladan Vucinic, Soraya Kharboutli, Ben-Niklas Baermann, Francis Ayuk, Uwe Platzbecker, Anca-Maria Albici, Nathalie Schub, Friederike Schmitz, Leyla Shune, Jack Khouri, Faiz Anwer, Shahzad
-
Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies Blood Cancer J. (IF 12.9) Pub Date : 2024-12-03 Zhongfei Tao, Zuzana Chyra, Jana Kotulová, Piotr Celichowski, Jana Mihályová, Sandra Charvátová, Roman Hájek
-
A comparative analysis of transformed indolent lymphomas and de novo diffuse large B-cell lymphoma: a population-based cohort study Blood Cancer J. (IF 12.9) Pub Date : 2024-11-29 John L. Vaughn, Angela Ramdhanny, Malak Munir, Sravani Rimmalapudi, Narendranath Epperla
Histologic transformation (HT) of indolent non-Hodgkin lymphoma (iNHL) to diffuse large B-cell lymphoma (DLBCL) carries a poor prognosis. Using the Surveillance, Epidemiology, and End Results-17 database, we conducted a population-based study of adult patients with transformed follicular lymphoma (t-FL), marginal zone lymphoma (t-MZL), lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (t-LPL/WM)
-
High level of circulating cell-free tumor DNA at diagnosis correlates with disease spreading and defines multiple myeloma patients with poor prognosis Blood Cancer J. (IF 12.9) Pub Date : 2024-11-28 Marina Martello, Vincenza Solli, Gaia Mazzocchetti, Antonio Giovanni Solimando, Davide Bezzi, Barbara Taurisano, Ajsi Kanapari, Andrea Poletti, Enrica Borsi, Silvia Armuzzi, Ilaria Vigliotta, Ignazia Pistis, Vanessa Desantis, Giulia Marzocchi, Ilaria Rizzello, Lucia Pantani, Katia Mancuso, Paola Tacchetti, Nicoletta Testoni, Cristina Nanni, Elena Zamagni, Michele Cavo, Carolina Terragna
-
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma Blood Cancer J. (IF 12.9) Pub Date : 2024-11-28 Narendranath Epperla, Melanie Lucero, Tom Bailey, Laura Mirams, Jolenta Cheung, Mona Amet, Gary Milligan, Lei Chen
-
Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies Blood Cancer J. (IF 12.9) Pub Date : 2024-11-28 Paul G. Richardson, Aurore Perrot, Joseph Mikhael, Thomas Martin, Meral Beksac, Ivan Spicka, Marcelo Capra, Mattia D’Agostino, Pieter Sonneveld, Kamlesh Bisht, Taro Fukao, Rick Zhang, Keisuke Tada, Christina Tekle, Sandrine Macé, Zandra Klippel, Helgi van de Velde, Philippe Moreau
-
Molecular monitoring in CML-a modern example of an old proverb. Blood Cancer J. (IF 12.9) Pub Date : 2024-11-28 Jeffrey H Lipton
-
Indolent nodal T follicular helper cell lymphomas—A case series Blood Cancer J. (IF 12.9) Pub Date : 2024-11-26 Jie Wang, Chun En Yau, Chen Ee Low, Mohamed Haniffa Bin Hasan Mohamed, Chee Leong Cheng, Jadee L. Neff, Jing Quan Lim, Soon Thye Lim, Jason Yongsheng Chan, Choon Kiat Ong, Valerie Shiwen Yang
-
CAR-T cell therapy in Multiple Myeloma: current status and future challenges Blood Cancer J. (IF 12.9) Pub Date : 2024-11-26 Dawn Swan, Deepu Madduri, Jay Hocking
-
RSK1 dependency in FLT3-ITD acute myeloid leukemia Blood Cancer J. (IF 12.9) Pub Date : 2024-11-26 Tim Kong, Angelo B. A. Laranjeira, Christopher T. Letson, LaYow Yu, Fan He, Aarthi Jayanthan, Gerrit Los, Sandra E. Dunn, Grant A. Challen, Stephen T. Oh
-
Venetoclax combined with three-day multi-frequency decitabine (DEC3-VEN) in elder or intensive chemotherapy ineligible patients with newly diagnosed acute myeloid leukemia. Blood Cancer J. (IF 12.9) Pub Date : 2024-11-20 Xiaohui Suo,Xiaojun Ma,Fang Zheng,Dongmei Wang,Guanchen Bai,Liyun Zhao,Zhongjing Han,Xin Lv,Congcong Zhang,Ju Wang,Kangxin Tuo,Zhen Meng,Shan Liu,Sifeng Gao,Jilei Zhang,Zongjiu Jiao,Jiaojie Song,Ling Li,Xinxiao Lu,Linyu Yuan,Kaiqi Liu,Xingli Zhao,Yingchang Mi
-
Frontline Ph-negative B-cell precursor acute lymphoblastic leukemia treatment and the emerging role of blinatumomab Blood Cancer J. (IF 12.9) Pub Date : 2024-11-19 Elias J. Jabbour, Hagop M. Kantarjian, Nicola Goekbuget, Bijal D. Shah, Sabina Chiaretti, Jae H. Park, Anita W. Rijneveld, Lia Gore, Shaun Fleming, Aaron C. Logan, Josep M. Ribera, Tobias F. Menne, Khalid Mezzi, Faraz Zaman, Kelly Velasco, Nicolas Boissel
-
What have we learned about TP53-mutated acute myeloid leukemia? Blood Cancer J. (IF 12.9) Pub Date : 2024-11-19 Moazzam Shahzad, Muhammad Kashif Amin, Naval G. Daver, Mithun Vinod Shah, Devendra Hiwase, Daniel A. Arber, Mohamed A. Kharfan-Dabaja, Talha Badar
-
Impact of TP53 mutation on genetic and cellular hierarchy profile in complex karyotype AML/MDS with increased blasts Blood Cancer J. (IF 12.9) Pub Date : 2024-11-15 Jinha Hwang, Ha Nui Kim, Jung Ah Kwon, Soo-Young Yoon, Min Ji Jeon, Eun Sang Yu, Dae Sik Kim, Chul Won Choi, Jung Yoon
-
A simplified, two-factor clinical prognostic scoring system for patients with newly diagnosed Hodgkins Lymphoma Blood Cancer J. (IF 12.9) Pub Date : 2024-11-11 Charanpreet Singh, Lekshmon KS, Arihant Jain, Deepesh Lad, Alka Khadwal, Rajender Basher, Amanjit Bal, Radhika Srinivasan, Subhash Varma, Pankaj Malhotra, Gaurav Prakash
-
Impact of lenalidomide-bortezomib-dexamethasone induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect® MM Registry Blood Cancer J. (IF 12.9) Pub Date : 2024-11-11 Sikander Ailawadhi, Hans C. Lee, James Omel, Kathleen Toomey, James W. Hardin, Cristina J. Gasparetto, Sundar Jagannath, Robert M. Rifkin, Brian G. M. Durie, Mohit Narang, Howard R. Terebelo, Prashant Joshi, Ying-Ming Jou, Jorge Mouro, Edward Yu, Rafat Abonour
-
Genetically determined telomere length in monoclonal gammopathy of undetermined significance, multiple myeloma risk and outcome. Blood Cancer J. (IF 12.9) Pub Date : 2024-11-11 Matteo Giaccherini,Alyssa I Clay-Gilmour,Romano Liotti,Angelica Macauda,Manuel Gentiluomo,Elizabeth E Brown,Mitchell J Machiela,Stephen J Chanock,Michelle A T Hildebrandt,Aaron D Norman,Elisabet Manasanch,S Vincent Rajkumar,Jonathan N Hofmann,Sonja I Berndt,Parveen Bhatti,Graham G Giles,Elad Ziv,Shaji K Kumar,Nicola J Camp,Wendy Cozen,Susan L Slager,Federico Canzian,Federica Gemignani,Celine M Vachon
-
Is CAR T a drug or a therapeutic pathway? Intention to treat versus per protocol analysis of real world studies of CAR-T cell therapy in relapsed refractory diffuse large B cell lymphoma Blood Cancer J. (IF 12.9) Pub Date : 2024-11-07 Rossana Di Staso, Beatrice Casadei, Frederick L. Locke, Michael Jain, Timothy J. Voorhees, Adam S. Kittai, Mariana Bastos-Oreiro, Antonio Gutiérrez, Alejandro Martin Garcia-Sancho, Maria Jose Terol, Monica Mead, Michael J. Maranzano, Gloria Iacoboni, Pere Barba, Mi Kwon, Rebeca Bailen, Juan Luis Reguera-Ortega, Agrima Mian, Brian Hill, Emmanuel Bachy, Franck Morschhauser, Roch Houot, Catherine Thieblemont
-
Proteasome inhibitors related thrombotic microangiopathy: a systematic and comprehensive review Blood Cancer J. (IF 12.9) Pub Date : 2024-11-07 Can Chen, Yiwei Li, Pengfei Shi, Shenxian Qian
-
Neutrophil-to-lymphocyte ratio as a prognostic indicator of mortality in Polycythemia Vera: insights from a prospective cohort analysis Blood Cancer J. (IF 12.9) Pub Date : 2024-11-06 Tiziano Barbui, Alessandra Carobbio, Arianna Ghirardi, Francesca Fenili, Maria Chiara Finazzi, Marta Castelli, Alessandro M. Vannucchi, Paola Guglielmelli, Alessandro Rambaldi, Naseema Gangat, Ayalew Tefferi
-
Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages Blood Cancer J. (IF 12.9) Pub Date : 2024-11-06 Yan Cheng, Fumou Sun, Daisy V. Alapat, Visanu Wanchai, David Mery, Eric R. Siegel, Hongwei Xu, Sarah Johnson, Wancheng Guo, Clyde Bailey, Cody Ashby, Michael Anton Bauer, Samer Al Hadidi, Carolina Schinke, Sharmilan Thanendrarajan, Maurizio Zangari, Frits van Rhee, Guido Tricot, John D. Shaughnessy, Fenghuang Zhan
-
Mosaic chromosomal alterations (mCAs) in individuals with monoclonal B-cell lymphocytosis (MBL) Blood Cancer J. (IF 12.9) Pub Date : 2024-11-06 Aswin Sekar, Rosalie Griffin, Sameer A. Parikh, Giulio Genovese, Dennis P. Robinson, Aaron D. Norman, Janet E. Olson, Kari G. Rabe, Mingma S. Hoel, Nicholas J. Boddicker, Paul J. Hampel, Neil E. Kay, James R. Cerhan, Esteban Braggio, Curtis A. Hanson, Celine M. Vachon, Tait D. Shanafelt, Benjamin L. Ebert, Susan L. Slager
-
The third generation AKR1C3-activated prodrug, ACHM-025, eradicates disease in preclinical models of aggressive T-cell acute lymphoblastic leukemia Blood Cancer J. (IF 12.9) Pub Date : 2024-11-06 Cara E. Toscan, Hannah McCalmont, Amir Ashoorzadeh, Xiaojing Lin, Zhe Fu, Louise Doculara, Hansen J. Kosasih, Roxanne Cadiz, Anthony Zhou, Sarah Williams, Kathryn Evans, Faezeh Khalili, Ruilin Cai, Kristy L. Yeats, Andrew J. Gifford, Russell Pickford, Chelsea Mayoh, Jinhan Xie, Michelle J. Henderson, Toby N. Trahair, Adam V. Patterson, Jeff B. Smaill, Charles E. de Bock, Richard B. Lock
-
Venous thromboembolism in adolescents and young adults with acute lymphoblastic leukemia treated on a pediatric-inspired regimen Blood Cancer J. (IF 12.9) Pub Date : 2024-10-31 Shai Shimony, Hari S. Raman, Yael Flamand, Julia Keating, Jonathan D. Paolino, Yannis K. Valtis, Andrew E. Place, Lewis B. Silverman, Stephen E. Sallan, Lynda M. Vrooman, Andrew M. Brunner, Donna S. Neuberg, Ilene Galinsky, Jacqueline S. Garcia, Eric S. Winer, Martha Wadleigh, Richard M. Stone, Jean M. Connors, Daniel J. DeAngelo, Marlise R. Luskin
-
Genomic profiles and outcomes in de novo versus therapy-related core binding factor AML Blood Cancer J. (IF 12.9) Pub Date : 2024-10-31 May Chiu, Aaron D. Schimmer, Andre C. Schuh, Aniket Bankar, Guillaume Richard-Carpentier, Hassan Sibai, Karen Yee, Marta Davidson, Steven M. Chan, Vikas Gupta, Dawn Maze
-
Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation Blood Cancer J. (IF 12.9) Pub Date : 2024-10-31 Oren Pasvolsky, Curtis Marcoux, Denái R. Milton, Babar Pal, Mark R. Tanner, Qaiser Bashir, Samer Srour, Jaehyun Lee, Neeraj Saini, Paul Lin, Jeremy Ramdial, Yago Nieto, Guilin Tang, Yosra Aljawai, Partow Kebriaei, Melody R. Becnel, Hans C. Lee, Krina K. Patel, Sheeba K. Thomas, Robert Z. Orlowski, Elizabeth J. Shpall, Richard E. Champlin, Muzaffar H. Qazilbash
-
Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors Blood Cancer J. (IF 12.9) Pub Date : 2024-10-25 Tiziano Barbui, Arianna Ghirardi, Alessandra Carobbio, Valerio De Stefano, Alessandro Rambaldi, Ayalew Tefferi, Alessandro M. Vannucchi
-
Drug development in higher-risk myelodysplastic syndromes. Blood Cancer J. (IF 12.9) Pub Date : 2024-10-24 Sangeetha Venugopal,Mikkael A Sekeres
-
The DLEU2/miR-15a/miR-16-1 cluster shapes the immune microenvironment of chronic lymphocytic leukemia Blood Cancer J. (IF 12.9) Pub Date : 2024-10-23 Ronghua Zhang, Priyanka Khare, Priyanka Banerjee, Cristina Ivan, Sarah Schneider, Federica Barbaglio, Karen Clise-Dwyer, Vanessa Behrana Jensen, Erika Thompson, Marisela Mendoza, Nicholas Chiorazzi, Shih-Shih Chen, Xiao-Jie Joy Yan, Nitin Jain, Paolo Ghia, Federico Caligaris-Cappio, Rima Mendonsa, Sashi Kasimsetty, Ryan Swoboda, Recep Bayraktar, William Wierda, Varsha Gandhi, George A. Calin, Michael
-
Results from Arm A of Phase 1/2 DREAMM-6 trial: belantamab mafodotin with lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma Blood Cancer J. (IF 12.9) Pub Date : 2024-10-21 Rakesh Popat, Bradley Augustson, Mercedes Gironella, Cindy Lee, Paul Cannell, Nashita Patel, Ravi S. Kasinathan, Rachel Rogers, Mehreen Shaikh, Amy Curry, Fernando Carreño, Sumita Roy-Ghanta, Joanna Opalinska, Hang Quach
-
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study Blood Cancer J. (IF 12.9) Pub Date : 2024-10-21 Niels W. C. J. van de Donk, Nizar Bahlis, Luciano J. Costa, María-Victoria Mateos, Ajay K. Nooka, Aurore Perrot, Alfred L. Garfall, Pragya Thaman, Keqin Qi, Clarissa Uhlar, Katherine Chastain, Margaret Doyle, Saad Z. Usmani
-
Publisher Correction: Patient preferences for intervention in the setting of precursor multiple myeloma. Blood Cancer J. (IF 12.9) Pub Date : 2024-10-21 Catherine R Marinac,Katelyn Downey,Jacqueline Perry,Brittany Fisher-Longden,Timothy R Rebbeck,Urvi A Shah,Elizabeth K O'Donnell,Irene M Ghobrial,Omar Nadeem,Brian L Egleston